Biolex Raises $60 Million

Biolex Inc., a Pittsboro, N.C.-based drug company whose lead candidate focuses on hepatitis C, has raised $60 million in Series D funding. Clarus Ventures led the round, and was joined by OrbiMed Advisors and return backers included Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corporation, Investor Growth Capital, Polaris Ventures, Mitsui & Co., The Dow Chemical Co., JP Morgan Securities and the North Carolina Economic Development Fund. Biolex has now raised nearly $160 million in total VC funding, and earlier this year canceled a planned $80 million IPO.

North AmericaUSBriefs